Featured Stock Update: Zoetis Inc. (NYSE:ZTS)

Zoetis Inc. (NYSE:ZTS) currently has a “Buy” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Buy” signal. While 20-Day Moving Average VS Current Price shows “Buy” Signal.

Zoetis Inc. (NYSE:ZTS) lost -0.89 Percent and closed its previous trading session at $92.4. The stock traded with the average Volume of 2.56 Million at the end of last session.

Zoetis Inc. (NYSE:ZTS) has the Market Capitalization of 44.7 Billion. The Stock has its 52-week High of $93.67 and 52-Week Low of $59.64 and it touched its 52-week high on 08/09/18 and 52-Week Low on 08/11/17


The company reported its last earnings Actual EPS of $0.77/share. While, the analyst predicted that the company could provide an EPS of $0.7/share. Hence the difference between Predicted EPS and Actual EPS reported is $0.07/share which shows an Earnings Surprise of 10 Percent.

Sell side analysts plays vital role in buying and selling a stock where 4 analysts rated Zoetis Inc. (NYSE:ZTS) as Buy, 0 analysts given Outperform signal, 1 reported Hold, and 1 analysts rated the stock as Sell.

The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 6.16% where SMA50 and SMA200 are 6.88% and 16.16% respectively.

The company shows its Return on Assets (ROA) value of 12.7%. The Return on Equity (ROE) value stands at 58%. While it’s Return on Investment (ROI) value is 16%.

Zoetis Inc. (NYSE:ZTS) currently has a Weekly Volatility of 1.85% percent while its Monthly Volatility is at 1.97% percent. While talking about Performance of the Stock, Zoetis Inc. currently has a Weekly performance of 1.06%, monthly performance percentage is 9.35 percent, Quarterly performance is 10.71 percent, 6 months performance shows a percent value of 29.21% and Yearly Performance is 51.95 percent.

Company Profile:

Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services.